Browse hierarchy: [Microbiology (MI)](/submissions/MI) → [Subpart D — Serological Reagents](/submissions/MI/subpart-d%E2%80%94serological-reagents) → [21 CFR 866.3200](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3200) → GPD — Antigen, Indirect Fluorescent Antibody Test, Echinococcus Granulosus

# GPD · Antigen, Indirect Fluorescent Antibody Test, Echinococcus Granulosus

_Microbiology · 21 CFR 866.3200 · Class 1_

**Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GPD

## Overview

- **Product Code:** GPD
- **Device Name:** Antigen, Indirect Fluorescent Antibody Test, Echinococcus Granulosus
- **Regulation:** [21 CFR 866.3200](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3200)
- **Device Class:** 1
- **Review Panel:** [Microbiology](/submissions/MI)

## Identification

Echinococcus spp. serological reagents are devices that consist of Echinococcus spp. antigens and antisera used in serological tests to identify antibodies to Echinococcus spp. in serum. The identification aids in the diagnosis of echinococcosis, caused by parasitic tapeworms belonging to the genus Echinococcus and provides epidemiological information on this disease. Echinococcosis is characterized by the development of cysts in the liver, lung, kidneys, and other organs formed by the larva of the infecting organisms.

## Classification Rationale

Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.

## Recent Cleared Devices (0 of 0)

_No cleared devices on record._

---

**Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GPD](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GPD)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com